|
1
|
Maher EA, Furnari FB, Bachoo RM, Rowitch
DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: Genetics
and biology of a grave matter. Genes Dev. 15:1311–1333. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Opel D, Westhoff MA, Bender A, Braun V,
Debatin KM and Fulda S: Phosphatidylinositol 3-kinase inhibition
broadly sensitizes glioblastoma cells to death receptor- and
drug-induced apoptosis. Cancer Res. 68:6271–6280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pollack IF, Jakacki RI, Blaney SM, Hancock
ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee
A, et al: Phase I trial of imatinib in children with newly
diagnosed brainstem and recurrent malignant gliomas: A Pediatric
Brain Tumor Consortium report. Neuro Oncol. 9:145–160. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prados MD, Chang SM, Butowski N, DeBoer R,
Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J,
Page M, et al: Phase II study of erlotinib plus temozolomide during
and after radiation therapy in patients with newly diagnosed
glioblastoma multiforme or gliosarcoma. J Clin Oncol. 27:579–584.
2009. View Article : Google Scholar :
|
|
6
|
Omuro AM, Faivre S and Raymond E: Lessons
learned in the development of targeted therapy for malignant
gliomas. Mol Cancer Ther. 6:1909–1919. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kelley SK and Ashkenazi A: Targeting death
receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol.
4:333–339. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bellail AC, Qi L, Mulligan P, Chhabra V
and Hao C: TRAIL agonists on clinical trials for cancer therapy:
The promises and the challenges. Rev Recent Clin Trials. 4:34–41.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hall MA and Cleveland JL: Clearing the
TRAIL for cancer therapy. Cancer Cell. 12:4–6. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
von Pawel J, Harvey JH, Spigel DR, Dediu
M, Reck M, Cebotaru CL, Humphreys RC, Gribbin MJ, Fox NL and
Camidge DR: Phase II trial of mapatumumab, a fully human agonist
monoclonal antibody to tumor necrosis factor-related
apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination
with paclitaxel and carboplatin in patients with advanced
non-small-cell lung cancer. Clin Lung Cancer. 15:188–196.e2. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Forero-Torres A, Infante JR, Waterhouse D,
Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, et
al: Phase 2, multicenter, open-label study of tigatuzumab
(CS-1008), a humanized monoclonal antibody targeting death receptor
5, in combination with gemcitabine in chemotherapy-naive patients
with unresectable or metastatic pancreatic cancer. Cancer Med.
2:925–932. 2013. View
Article : Google Scholar
|
|
13
|
Takeda K, Stagg J, Yagita H, Okumura K and
Smyth MJ: Targeting death-inducing receptors in cancer therapy.
Oncogene. 26:3745–3757. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2005. View Article : Google Scholar
|
|
15
|
Russo M, Mupo A, Spagnuolo C and Russo GL:
Exploring death receptor pathways as selective targets in cancer
therapy. Biochem Pharmacol. 80:674–682. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang A, Wilson NS and Ashkenazi A:
Proapoptotic DR4 and DR5 signaling in cancer cells: Toward clinical
translation. Curr Opin Cell Biol. 22:837–844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim EH, Kim HS, Kim SU, Noh EJ, Lee JS and
Choi KS: Sodium butyrate sensitizes human glioma cells to
TRAIL-mediated apoptosis through inhibition of Cdc2 and the
subsequent down-regulation of survivin and XIAP. Oncogene.
24:6877–6889. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Premkumar DR, Jane EP, Foster KA and
Pollack IF: Survivin inhibitor YM-155 sensitizes tumor necrosis
factor-related apoptosis-inducing ligand-resistant glioma cells to
apoptosis through Mcl-1 downregulation and by engaging the
mitochondrial death pathway. J Pharmacol Exp Ther. 346:201–210.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jane EP, Premkumar DR and Pollack IF:
Bortezomib sensitizes malignant human glioma cells to TRAIL,
mediated by inhibition of the NF-{kappa}B signaling pathway. Mol
Cancer Ther. 10:198–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Opel D, Naumann I, Schneider M, Bertele D,
Debatin KM and Fulda S: Targeting aberrant PI3K/Akt activation by
PI103 restores sensitivity to TRAIL-induced apoptosis in
neuroblastoma. Clin Cancer Res. 17:3233–3247. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Okhrimenko H, Lu W, Xiang C, Hamburger N,
Kazimirsky G and Brodie C: Protein kinase C-epsilon regulates the
apoptosis and survival of glioma cells. Cancer Res. 65:7301–7309.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Salmena L, Carracedo A and Pandolfi PP:
Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maira SM, Pecchi S, Huang A, Burger M,
Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al:
Identification and characterization of NVP-BKM120, an orally
available pan-class I PI3-kinase inhibitor. Mol Cancer Ther.
11:317–328. 2012. View Article : Google Scholar
|
|
24
|
Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li
H, Lin H, Lan Y, Liu Z, He J, et al: Novel phosphatidylinositol
3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells
and shows synergistic anti-myeloma activity with dexamethasone. J
Mol Med Berl. 90:695–706. 2012. View Article : Google Scholar
|
|
25
|
Koul D, Fu J, Shen R, LaFortune TA, Wang
S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, et al: Antitumor
activity of NVP-BKM120 - a selective pan class I PI3 kinase
inhibitor showed differential forms of cell death based on p53
status of glioma cells. Clin Cancer Res. 18:184–195. 2012.
View Article : Google Scholar
|
|
26
|
Brachmann SM, Kleylein-Sohn J, Gaulis S,
Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger
M, Stauffer F, Vaxelaire J, et al: Characterization of the
mechanism of action of the pan class I PI3K inhibitor NVP-BKM120
across a broad range of concentrations. Mol Cancer Ther.
11:1747–1757. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bendell JC, Rodon J, Burris HA, de Jonge
M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, et
al: Phase I, dose-escalation study of BKM120, an oral pan-Class I
PI3K inhibitor, in patients with advanced solid tumors. J Clin
Oncol. 30:282–290. 2012. View Article : Google Scholar
|
|
28
|
Ren H, Zhao L, Li Y, Yue P, Deng X,
Owonikoko TK, Chen M, Khuri FR and Sun SY: The PI3 kinase inhibitor
NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation,
contributing to induction of apoptosis and enhancement of
TRAIL-induced apoptosis. Cancer Lett. 338:229–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Premkumar DR, Jane EP, DiDomenico JD,
Vukmer NA, Agostino NR and Pollack IF: ABT-737 synergizes with
bortezomib to induce apoptosis, mediated by Bid cleavage, Bax
activation, and mitochondrial dysfunction in an Akt-dependent
context in malignant human glioma cell lines. J Pharmacol Exp Ther.
341:859–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jane EP, Premkumar DR, DiDomenico JD, Hu
B, Cheng SY and Pollack IF: YM-155 potentiates the effect of
ABT-737 in malignant human glioma cells via survivin and Mcl-1
down-regulation in an EGFR-dependent context. Mol Cancer Ther.
12:326–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tait SW and Green DR: Mitochondria and
cell death: Outer membrane permeabilization and beyond. Nat Rev Mol
Cell Biol. 11:621–632. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim SH, Ricci MS and El-Deiry WS: Mcl-1: A
gateway to TRAIL sensitization. Cancer Res. 68:2062–2064. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ricci MS, Kim SH, Ogi K, Plastaras JP,
Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, et al:
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib
sensitizes resistant human cancer cells to TRAIL-induced death.
Cancer Cell. 12:66–80. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Naumann I, Kappler R, von Schweinitz D,
Debatin KM and Fulda S: Bortezomib primes neuroblastoma cells for
TRAIL-induced apoptosis by linking the death receptor to the
mitochondrial pathway. Clin Cancer Res. 17:3204–3218. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Suhara T, Kim HS, Kirshenbaum LA and Walsh
K: Suppression of Akt signaling induces Fas ligand expression:
Involvement of caspase and Jun kinase activation in Akt-mediated
Fas ligand regulation. Mol Cell Biol. 22:680–691. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Uriarte SM, Joshi-Barve S, Song Z, Sahoo
R, Gobejishvili L, Jala VR, Haribabu B, McClain C and Barve S: Akt
inhibition upregulates FasL, downregulates c-FLIPs and induces
caspase-8-dependent cell death in Jurkat T lymphocytes. Cell Death
Differ. 12:233–242. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chakravarti A, Zhai G, Suzuki Y, Sarkesh
S, Black PM, Muzikansky A and Loeffler JS: The prognostic
significance of phosphatidylinositol 3-kinase pathway activation in
human gliomas. J Clin Oncol. 22:1926–1933. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rychahou PG, Murillo CA and Evers BM:
Targeted RNA interference of PI3K pathway components sensitizes
colon cancer cells to TNF-related apoptosis-inducing ligand
(TRAIL). Surgery. 138:391–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim S, Kang J, Qiao J, Thomas RP, Evers BM
and Chung DH: Phosphatidylinositol 3-kinase inhibition
down-regulates survivin and facilitates TRAIL-mediated apoptosis in
neuroblastomas. J Pediatr Surg. 39:516–521. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bagci-Onder T, Wakimoto H, Anderegg M,
Cameron C and Shah K: A dual PI3K/mTOR inhibitor, PI-103,
cooperates with stem cell-delivered TRAIL in experimental glioma
models. Cancer Res. 71:154–163. 2011. View Article : Google Scholar
|
|
41
|
Chen L, Willis SN, Wei A, Smith BJ,
Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC:
Differential targeting of prosurvival Bcl-2 proteins by their
BH3-only ligands allows complementary apoptotic function. Mol Cell.
17:393–403. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Okumura K, Huang S and Sinicrope FA:
Induction of Noxa sensitizes human colorectal cancer cells
expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor,
ABT-737. Clin Cancer Res. 14:8132–8142. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kischkel FC, Lawrence DA, Chuntharapai A,
Schow P, Kim KJ and Ashkenazi A: Apo2L/TRAIL-dependent recruitment
of endogenous FADD and caspase-8 to death receptors 4 and 5.
Immunity. 12:611–620. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Seol DW: p53-Independent up-regulation of
a TRAIL receptor DR5 by proteasome inhibitors: A mechanism for
proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem
Biophys Res Commun. 416:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kim IY, Kang YJ, Yoon MJ, Kim EH, Kim SU,
Kwon TK, Kim IA and Choi KS: Amiodarone sensitizes human glioma
cells but not astrocytes to TRAIL-induced apoptosis via
CHOP-mediated DR5 upregulation. Neuro Oncol. 13:267–279. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim EH, Yoon MJ, Kim SU, Kwon TK, Sohn S
and Choi KS: Arsenic trioxide sensitizes human glioma cells, but
not normal astrocytes, to TRAIL-induced apoptosis via
CCAAT/enhancer-binding protein homologous protein-dependent DR5
up-regulation. Cancer Res. 68:266–275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ding L, Yuan C, Wei F, Wang G, Zhang J,
Bellail AC, Zhang Z, Olson JJ and Hao C: Cisplatin restores TRAIL
apoptotic pathway in glioblastoma-derived stem cells through
up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest.
29:511–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang J, Xu F, Zhu D, Duan Y, Chen J, Sun
X, He X, Li P, Sun W and Feng J: Schistosoma japonicum soluble egg
antigens facilitate hepatic stellate cell apoptosis by
downregulating Akt expression and upregulating p53 and DR5
expression. PLoS Negl Trop Dis. 8:e31062014. View Article : Google Scholar : PubMed/NCBI
|
